Takashima Shuichiro, Miyamoto Toshihiro, Kamimura Tomohiko, Yoshimoto Goichi, Yoshida Shuro, Henzan Hideho, Takase Ken, Kato Koji, Ito Yoshikiyo, Ohno Yuju, Nagafuji Koji, Eto Tetsuya, Techima Takanori, Akashi Koichi
Int J Hematol. 2015 Dec;102(6):689-96. doi: 10.1007/s12185-015-1883-0.
We retrospectively analyzed the outcomes of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who underwent first allogeneic stem cell transplantation (allo-SCT) at complete remission (CR) with myeloablative conditioning (MAC, n = 31) or reduced-intensity conditioning (RIC, n = 15) between 2001 and 2012. All the patients had received tyrosine kinase inhibitor (TKI)-based chemotherapy prior to allo-SCT. Overall survival (OS) rates (57 vs 63%, p = 0.53), leukemia-free survival rates (50 vs 65%, p = 0.29), and non-relapse mortality rates (39 vs 35%, p = 0.62) at 2 years were similar between the MAC and RIC groups. The minimal residual disease (MRD) status evaluated by sensitive polymerase chain reaction prior to allo-SCT did not influence the OS rate (77 vs 54%, p = 0.28) and leukemia-free survival rate (69 vs 51%, p = 0.48), irrespective of the conditioning intensity. Our data suggest that the RIC regimen may represent a sufficient intensity of therapeutic pre-transplant conditioning for patients with Ph+ALL who have maintained a hematological CR with TKI-combined chemotherapy.
我们回顾性分析了2001年至2012年间接受首次异基因干细胞移植(allo-SCT)的费城染色体阳性急性淋巴细胞白血病(Ph+ALL)患者的结局,这些患者在完全缓解(CR)时接受了清髓性预处理(MAC,n = 31)或减低强度预处理(RIC,n = 15)。所有患者在allo-SCT之前均接受了基于酪氨酸激酶抑制剂(TKI)的化疗。MAC组和RIC组在2年时的总生存率(OS)(57% 对 63%,p = 0.53)、无白血病生存率(50% 对 65%,p = 0.29)和非复发死亡率(39% 对 35%,p = 0.62)相似。在allo-SCT之前通过敏感聚合酶链反应评估的微小残留病(MRD)状态,无论预处理强度如何,均不影响OS率(77% 对 54%,p = 0.28)和无白血病生存率(69% 对 51%,p = 0.48)。我们的数据表明,对于通过TKI联合化疗维持血液学CR的Ph+ALL患者,RIC方案可能代表了足够强度的移植前治疗预处理。